Hi, this is Theresa Agnew, CEO of BioGaia. Theresa, Alexander, and I are here to share our Q2 results. For Q2, our sales were 384 million SEK, which is a growth of 22%. That was mainly driven by growth in the APAC region as well as our Americas region. Sales in Europe, the Middle East, and Africa increased by 7%. Sales in Asia Pacific increased by 49% and in the Americas by 22%. We did have some orders affected due to quarterly variations in specific areas, particularly in China and Brazil. Our EBIT was 134 million MSEK, which is a growth of 42%, and our EBIT margin is 35%. Earlier in the month of June, we announced that we are taking our business direct in Australia and New Zealand. This is really exciting for us. It is one of our future investments. Australia is actually the 12th largest probiotics market in the world, and we have a really big opportunity to grow in both Australia and New Zealand. These are both markets where consumers understand probiotics, and we are introducing our probiotics drops initially, followed by an expansion of our other probiotic products in the future through the pharmacy and grocery channels in Australia and New Zealand. It's a big opportunity for us in terms of taking our business direct. And as you know, we have been successful in our other direct businesses. Previously, we were directly present in six markets. So now that makes it eight markets. Our direct business typically accounts for around 30% of our sales. So we anticipate this will continue to grow, as we've taken Australia and New Zealand direct now. Also on the news front, in early July we won our arbitration with our former Italian distributor. And we have recently, just last week, signed a long-term contract with our sub-distributor, Recordati, which is a pharmaceutical company in Italy, Spain, Portugal, and a number of other markets, so they will now be our exclusive distributor of probiotics in Italy, as well as in Spain and Portugal. As you know, over the past couple of quarters, we have been discussing future investments in our business to continue our growth. So we are ramping up our investments. In the second half of this year, we are projecting 75 to 85 million in costs, on top of our normal operating expenses. Some of those investments will be in marketing and sales activities. Specifically, we will focus on the US with a sales force that will be marketing and selling our probiotics products. As we mentioned, we are launching our direct business in Australia and New Zealand, which presents another investment opportunity for us. We will also be launching our first global advertising campaign and preparing for that launch. That will be coming up in the near term. We are also investing in new products in R&D, and in clinical studies for the future. So these are just some of the investments that we will be making to drive our continued growth. Some of the launch events and other activities in the quarter. Through our Pharmabest distributor in Italy, we launched our BioGaia Protectis drops with vitamin D, and in the UK, which is one of our direct markets, we launched our BioGaia Prodentis lozenges. As we've discussed before, Prodentis is one of the brands we are continuing to invest in. We've done extremely well in Japan, the US, and Canada.
And now we are placing even more emphasis on products in the UK. As I mentioned in the overall introduction, we have announced our own distribution in Australia and New Zealand, and also announced our long-term agreement with Recordati in the Italian market. As previously mentioned, our sales increased by 22%. Our pediatric sales increased by 32%, mainly due to increased sales of our Protectis drops and an overall increase in sales across all regions, especially in markets such as China, Brazil, and Canada. For the quarter, our adult sales decreased by 6% due to decreased sales of our Prodentis tablets, mainly in South Africa, Belgium, and Japan.
However, this is due to quarterly variations for individual orders. As you can see, for the year to date, our overall pediatric growth is at 11% and our overall adult health growth is at 10%. Thus, our pediatric business accounts for about 79% of our total business. In terms of the regions, as I said earlier. EMEA sales increased by 7%. This increase was primarily in Germany, Spain, and Turkey.
In the Asia Pacific, our sales increased by 49%. This was mainly in China, South Korea, and Vietnam. Again, our sales were positively impacted by quarterly variations, and in the Americas, our sales grew by 22%, primarily in the US, Canada, and Brazil. Again, our sales for the quarter were positively influenced by quarterly variations, specifically in Brazil. But as you can also see, our year-to-date growth in EMEA is 10%, in Asia Pacific is 25%, and in the Americas is 3% for a total year-to-date growth of 11%.
I will now hand over to Alex to discuss the financials in more detail.